ReviewFrontiers in immunology2018
Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer.
Review in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05765084 (Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma), which is not on this map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma
Who cites it
63 citing papers in PubMed, 93 citations in OpenAlex.
- Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial.Nature communications · 2024Trial
- Immunological responses to adjuvant vaccination with combined CD1cOncoimmunology · 2022Trial
- A phase I/II feasibility vaccine study by autologous leukemic apoptotic corpse-pulsed dendritic cells for elderly AML patients.Human vaccines & immunotherapeutics · 2021Trial
- TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma.Journal for immunotherapy of cancer · 2020Trial
- A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis.Journal for immunotherapy of cancer · 2018Trial
- Advances inMolecular therapy. Nucleic acids · 2026Review
- Deciphering the Dysregulated Pathways and Candidate Therapeutic Compounds for Primary Ovarian Cancer Using Whole Transcriptomics Data and Next Generation Knowledge Discovery Strategies.Journal of cellular and molecular medicine · 2026Article
- Dual targeting of PD-1/PD-L1 and iL-33/ST2 signalling pathways: a promising approach in breast cancer immunotherapy.Annals of medicine · 2025Review
- Single-Cell Profiling Reveals Global Immune Responses During the Progression of Murine Epidermal Neoplasms.Cancers · 2025Article
- Comparison of Antitumor Effects of Combinations of Immune Checkpoint Inhibitors With Dendritic Cells Intratumorally Injected into Irradiated Mouse Adenocarcinoma.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2025Article
- Immune checkpoints and ncRNAs: pioneering immunotherapy approaches for hematological malignancies.Cancer cell international · 2024Review
- Dendritic cell-based immunotherapy in non-small cell lung cancer: a comprehensive critical review.Frontiers in immunology · 2024Review
- Co-delivery of dendritic cell vaccine and anti-PD-1 antibody with cryomicroneedles for combinational immunotherapy.Bioengineering & translational medicine · 2023Article
- Advances in PD-1 signaling inhibition-based nano-delivery systems for tumor therapy.Journal of nanobiotechnology · 2023Review
- Skin basal cell carcinomas assemble a pro-tumorigenic spatially organized and self-propagating Trem2+ myeloid niche.Nature communications · 2023Article
- Leveraging a powerful allogeneic dendritic cell line towards neoantigen-based cancer vaccines.Genes & cancer · 2023Article
- Combining PD-1/PD-L1 blockade with type I interferon in cancer therapy.Frontiers in immunology · 2023Review
- Programmed Cell Death-Ligand 1 in Head and Neck Squamous Cell Carcinoma: Molecular Insights, Preclinical and Clinical Data, and Therapies.International journal of molecular sciences · 2022Review
- Clinical relevance and therapeutic aspects of professional antigen-presenting cells in lung cancer.Medical oncology (Northwood, London, England) · 2022Review
- LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Two decades of clinical cancer research with dendritic cell (DC)-based vaccination have proved that this type of personalized medicine is safe and has the capacity to improve survival, but monotherapy is unlikely to cure the cancer. Designed to empower the patient's antitumor immunity, huge research efforts are set to improve the efficacy of next-generation DC vaccines and to find synergistic combinations with existing cancer therapies. Immune checkpoint approaches, aiming to breach immune suppression and evasion to reinforce antitumor immunity, have been a revelation in the immunotherapy field. Early success of therapeutic antibodies blocking the programmed death-1 (PD-1) pathway has sparked the development of novel inhibitors and combination therapies. Hence, merging immunoregulatory tumor-specific DC strategies with PD-1-targeted approaches is a promising path to explore. In this review, we focus on the role of PD-1-signaling in DC-mediated antitumor immunity. In the quest of exploiting the full potential of DC therapy, different strategies to leverage DC immunopotency by impeding PD-1-mediated immune regulation are discussed, including the most advanced research on targeted therapeutic antibodies, lessons learned from chemotherapy-induced immune activation, and more recent developments with soluble molecules and gene-silencing techniques. An overview of DC/PD-1 immunotherapy combinations that are currently under preclinical and clinical investigation substantiates the clinical potential of such combination strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.